The FDA approved a new PrEP formulation from Gilead Sciences on June 27, 2025, noting the disproportionate impact of HIV in sub-Saharan Africa.

The entities involved

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• Gilead Sciences →

  American company

  • Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.Sun 22:40
  • A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.Sat 01:51
• Africa →

  continent

  • Ghana hosts a global conference on reparatory justice, debating colonial legacy and the government-backed repeal of the Code Noir.Mon 17:37
  • El Nino is causing global weather patterns to bring heat and dryness to various regions, testing global food output.Mon 16:37

Related events

• Gilead Sciences provided an HIV prevention drug consignment to a Zambian hospital, funded by the US.Sep 2
• George W. Bush launched PEPFAR to fight HIV in Africa, while the Trump administration's aid cuts threaten global health initiatives.Jul 21
• Gilead Sciences acquired Arcellx and presented priorities at a Wells Fargo conference, while also discussing submissions with the FDA and CDC.Sep 10